- Intel survey: Patients ready to embrace personalized medicine
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- Tender Corp. highlights After Bite Kids insect bite treatment
- PhRMA report lists 271 vaccines in development
HACKENSACK, N.J. — An organization focused on a fatal genetic disorder that affects men has launched a mobile app that allows for the location of clinical trials and clinics.
Parent Project Muscular Dystrophy announced the launch of the Duchenne Central mobile app for Apple and Android devices, which it developed with Siren Interactive. Duchenne muscular dystrophy slowly robs young men of their muscle strength; there is currently no Food and Drug Administration-approved treatment for it, but there are treatments undergoing clinical trials. Duchenne is the most common fatal genetic disorder diagnosed in childhood, with about 20,000 new cases diagnosed annually and most patients living into their late 20s, according to PPMD.
"It is essential that patients and their families have ongoing access to information on the latest clinical trials," PPMD president and CEO Pat Furlong said. "We are proud to bring this new resource to the Duchenne community."